Alnylam Pharma (ALNY) Tops Q1 EPS by 4c

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.62), $0.04 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $18.51 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• Pony AI (PONY) Reports Revenue Above Estimates
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c